Teriparatide LA is a recombinant peptide commercialized by Shenzhen Salubris Pharmaceuticals, with a leading Phase III program in Post Menopausal Osteoporosis. According to Globaldata, it is involved in 2 clinical trials, of which 1 was completed, and 1 is ongoing. GlobalData uses proprietary data and analytics to provide a complete picture of Teriparatide LAs valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
Smarter leaders trust GlobalData
The revenue for Teriparatide LA is expected to reach an annual total of $108 mn by 2036 globally based off GlobalDatas Expiry Model. The drugs revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drugs phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
Teriparatide LA Overview
SAL-056 (long-acting teriparatide) is under development for the treatment of osteoporosis in postmenopausal women. The drug candidate acts by targeting parathyroid hormone receptor. It is administered through subcutaneous route.
Shenzhen Salubris Pharmaceuticals Overview
Shenzhen Salubris Pharmaceuticals (Salubris) focuses on the research, development, manufacture and distribution of pharmaceutical products. The company’s pipeline products include sacubitril allisartan calcium (S086), allisartan isoproxilamlodipine besylate tablets, allisartan isoproxilindapamide sustained-release tablets, enarodustat (SAL0951), SAL0104, SAL007, SAL003, SAL056P, SAL001, SAL02, fotagliptin, SAL015 and SAL0112, among others. Salubris is investigating small molecules and biological therapeutics for the treatment of metabolic, oncology and also bone diseases. The company also develops interventional medical devices for cardiology, cerebrovascular, structural heart and peripheral vascular disease areas. It operates in the US, Germany, France and Japan. Salubris is headquartered in Shenzhen, Guangdong, China.
The company reported revenues of (Renminbi) CNY3,365.3 million for the fiscal year ended December 2023 (FY2023), a decrease of 3.4% over FY2022. In FY2023, the companys operating margin was 19.4%, compared to an operating margin of 20.9% in FY2022. In FY2023, the company recorded a net margin of 17.2%, compared to a net margin of 18.3% in FY2022.
The company reported revenues of CNY1,091 million for the first quarter ended March 2024, an increase of 20% over the previous quarter.
For a complete picture of Teriparatide LAs valuation, buy the drugs risk-adjusted NPV model (rNPV) here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.
The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.
